Answers are grounded in this paper and cite their sources.
This study demonstrates methods for identifying sulfated and O-acetylated N-glycans in IgA, suggesting deeper insights into their immune functions.
Sulfated N- glycans from human immunoglobulin A (IgA) were recently discovered via glycomic approaches. However, their site-specific description is still pending. Certain N- glycan structures at specific N- glycosylation sites in IgA are crucial for microbial neutralization and effector functions. For instance, sialylated N- glycans on the C-terminal tailpiece mediate anti-viral activity by interfering with sialic-acid-binding viruses. Sulfated N- glycan epitopes can be ligands for viral proteins and thus play a role in the immune response. In this study, we performed a site-specific screening for sulfated and other rare N- glycans in two commercially available human serum IgA samples employing an in-depth N- glycoproteomic approach, previously developed by us. We found evidence of complex-type and hybrid-type N- glycans containing sulfated N- acetylhexosamine (sulfated HexNAc) attached to the N- glycosylation sites in the tailpiece and the C H 2 domain of both IgA subclasses. Also, complex-type N- glycan compositions bearing O- acetylated sialic acid were identified primarily at the tailpiece site. Surprisingly, N- glycans bearing glucuronic acid were identified in the commercial IgA samples, but from peptides of “contaminant” glycoproteins. A detailed comparison of the N- glycosylation profiles of human serum IgA samples from two suppliers showed such N- glycans with sulfated HexNAc consistently in higher abundance in the tailpiece region. These findings have not been described before for a site-specific glycopeptide analysis. Overall, our work provides strategies for performing a dedicated site-specific search for sulfated and O- acetylated N- glycans that can be easily transferred, e.g., to human IgA derived from mucosal tissues, milk, or saliva. We expect that a wider and deeper micro-heterogeneity description of clinically relevant glycoproteins, such as immunoglobulins, can expand the screening for biomarkers or treatment options.
No takes yet. Share an insight, caveat, or question.
Zuniga-Banuelos et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: